Leerink Partnrs Issues Positive Outlook for PTCT Earnings

Key Points

• Leerink Partners has revised its Q3 2025 earnings estimate for PTC Therapeutics, anticipating a loss of ($1.17) per share, slightly improved from the prior estimate of ($1.20).
• PTC Therapeutics previously reported Q2 earnings of ($0.83) per share, exceeding analysts' expectations, with a revenue of $178.88 million for the same quarter.
• The stock is currently rated as a "Moderate Buy" by analysts, with an average target price set at $69.00, while insiders have recently sold a significant number of shares, totaling over $15.5 million.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Research analysts at Leerink Partnrs upped their Q3 2025 earnings estimates for PTC Therapeutics in a note issued to investors on Wednesday, October 8th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings of ($1.17) per share for the quarter, up from their prior estimate of ($1.20). The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share. Leerink Partnrs also issued estimates for PTC Therapeutics' Q4 2025 earnings at ($1.19) EPS, FY2025 earnings at $8.33 EPS, Q1 2026 earnings at ($1.32) EPS, Q2 2026 earnings at ($1.26) EPS, Q3 2026 earnings at ($0.60) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($2.93) EPS and FY2027 earnings at ($2.84) EPS.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.24. The business had revenue of $178.88 million during the quarter, compared to the consensus estimate of $173.01 million. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. PTC Therapeutics's revenue for the quarter was down 4.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.29) earnings per share. PTC Therapeutics has set its FY 2025 guidance at EPS.

Several other research analysts have also recently weighed in on the stock. Morgan Stanley reduced their price target on shares of PTC Therapeutics from $76.00 to $71.00 and set an "overweight" rating for the company in a report on Wednesday, August 20th. Barclays upped their price target on shares of PTC Therapeutics from $42.00 to $46.00 and gave the company an "equal weight" rating in a report on Tuesday, July 29th. Truist Financial upped their price target on shares of PTC Therapeutics from $80.00 to $86.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Citigroup increased their target price on shares of PTC Therapeutics from $40.00 to $50.00 and gave the stock a "neutral" rating in a report on Monday, July 28th. Finally, UBS Group increased their target price on shares of PTC Therapeutics from $71.00 to $80.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Nine equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $69.00.

PTC Therapeutics Stock Performance

Shares of NASDAQ PTCT opened at $66.23 on Monday. The stock has a market cap of $5.26 billion, a P/E ratio of 9.50 and a beta of 0.55. The firm has a 50 day moving average price of $55.73 and a 200 day moving average price of $50.50. PTC Therapeutics has a 52-week low of $35.51 and a 52-week high of $67.40.

Insiders Place Their Bets

In other news, VP Mark Elliott Boulding sold 24,585 shares of the firm's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $61.34, for a total value of $1,508,043.90. Following the sale, the vice president directly owned 103,901 shares in the company, valued at approximately $6,373,287.34. This trade represents a 19.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Eric Pauwels sold 39,850 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $56.92, for a total transaction of $2,268,262.00. Following the completion of the sale, the insider owned 72,912 shares in the company, valued at approximately $4,150,151.04. The trade was a 35.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 252,251 shares of company stock valued at $15,592,111 in the last three months. Insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP raised its holdings in PTC Therapeutics by 545.5% during the 1st quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 551 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in PTC Therapeutics by 84.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock worth $36,000 after purchasing an additional 320 shares during the last quarter. GAMMA Investing LLC raised its holdings in PTC Therapeutics by 86.3% during the 1st quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 441 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in PTC Therapeutics by 247.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 814 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in PTC Therapeutics during the 1st quarter worth approximately $61,000.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.